Page last updated: 2024-11-05

clothiapine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281055
CHEMBL ID843
CHEBI ID8892
SCHEMBL ID19023
MeSH IDM0224730
PubMed CID16351
CHEMBL ID304902
CHEBI ID108591
CHEBI ID31424
SCHEMBL ID122941
MeSH IDM0224730

Synonyms (159)

Synonym
AC-737
unii-kx2339dp44
kx2339dp44 ,
rosiglitazone xr
nsc 717764
155141-29-0
rosiglitazone maleate ,
nsc-717764
rosiglitazone maleate [usan]
brl 49653-c
venvia
(+-)-5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1)
nyracta
brl-49653c
2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2z)-2-butenedioate (1:1)
5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2z)-but-2-enedioate
CHEBI:8892 ,
MLS001401426
smr000471612
nsc717764
2, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2z)-2-butenedioate (1:1)
D00596
avandia (tn)
rosiglitazone maleate (jan/usp)
MLS001306472
avandamet
HMS2051B11
rosiglitzazone maleate
CHEMBL843
brl-49653-c
A809615
5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleate
tox21_302367
NCGC00255233-01
dtxcid703569
dtxsid2023569 ,
cas-155141-29-0
HMS2233I10
AKOS015961534
CCG-100943
S2505
rosiglitazone maleate [mi]
rosiglitazone maleate [usp monograph]
rosiglitazone maleate [mart.]
rosiglitazone maleate [orange book]
(+/-)-5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1)
5-((4-(2-(n-methyl-n-2-pyridylamino)ethoxy)phenyl)methyl)thiazolidine-2,4-dione maleate
rosiglitazone maleate [who-dd]
rosiglitazone maleate [usp-rs]
rosiglitazone maleate [jan]
rosiglitazone maleate [vandf]
CCG-208126
CS-1692
rosiglitazone (maleate) ,
HY-14600
NC00193
SCHEMBL19023
KS-5027
SUFUKZSWUHZXAV-BTJKTKAUSA-N
5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate
5-[4-[2-[n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate
5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione maleate
HB4140
(2z)-but-2-enedioic acid; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
SW197573-4
Q27888042
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione maleate
mfcd03427306
5-{4-[2-(methylpyridin-2-ylamino)ethoxy]benzyl}thiazolidine-2,4-dione maleate
2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2z)-2-butenedioate (1:1)
(z)-but-2-enedioate;2-[4-[(2,4-dioxo-1,3-thiazolidin-3-ium-5-yl)methyl]phenoxy]ethyl-methyl-pyridin-2-ylazanium
HMS3884H04
(z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
rosiglitazonemaleate
BR164376
rosiglitazone maleate- bio-x
EN300-1692904
5-(p-(2-(methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione monomaleate
rosiglitazone maleate (usp monograph)
(+/-)-5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, (z)-2-butenedioate (1:1)
rosiglitazone maleate (mart.)
rosiglitazone maleate (usp-rs)
bdbm50040237
2-chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]thiazepine
2-chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]thiazepine(clothiapine)
BRD-K10990317-001-01-1
dibenzo[b,f][1,4]thiazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
clothiapine
2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine
s-805c
entumin
2-chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine
clotiapine
clotiapina [inn-spanish]
brn 0568276
einecs 218-162-8
entumine
clotiapinum [inn-latin]
dibenzo(b,f)(1,4)thiazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
etumine
2-chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine
hf 2159
BPBIO1_001137
PDSP1_000469
PDSP2_000467
BIOMOL-NT_000008
NCGC00160387-01
clotiapine (jan/inn)
entumin (tn)
2058-52-8
clothiapine (usan)
D01597
NCGC00160387-02
CHEBI:108591
8-chloro-6-(4-methyl-1-piperazinyl)benzo[b][1,4]benzothiazepine
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine
HMS2089L15
hf-2159 ,
CHEMBL304902 ,
AKOS005065858
NCGC00160387-03
z05hcy0x1t ,
clotiapinum
w 130
clotiapine [inn]
unii-z05hcy0x1t
lw 2159
clotiapina
clothiapine [usan]
dtxcid702851
tox21_111779
cas-2058-52-8
dtxsid5022851 ,
FT-0603194
clothiapine [mi]
clotiapine [mart.]
clotiapine [who-dd]
clotiapine [jan]
SCHEMBL122941
tox21_111779_1
NCGC00160387-04
2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine
AB01275460-01
kinetinriboside
SR-05000001467-1
sr-05000001467
CHEBI:31424
J-013441
MRF-0000024
(e)-2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine
BCP06511
Q3661095
DB13256
BRD-K10990317-001-02-9
hf2159
HY-117083
EN300-26485788
13-chloro-10-(4-methylpiperazin-1-yl)-2-thia-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
CS-0063673

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
maleate saltSalts from maleic acid.
dibenzothiazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency70.57470.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency39.68710.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency47.06720.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency20.83200.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency20.83200.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency2.04420.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency20.13190.000221.22318,912.5098AID743035; AID743036; AID743042; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency17.12390.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency60.75780.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency48.26160.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency36.73210.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.95630.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.75780.001530.607315,848.9004AID1224848; AID1224849
farnesoid X nuclear receptorHomo sapiens (human)Potency31.19530.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency54.15040.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.89690.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency6.11960.001024.504861.6448AID743212; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.01150.001019.414170.9645AID743094; AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency18.08590.023723.228263.5986AID743222; AID743223
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency5.41500.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency21.74130.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency56.31030.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency36.73210.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.94670.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency60.75780.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency2.41880.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency60.75780.001551.739315,848.9004AID1259244
Guanine nucleotide-binding protein GHomo sapiens (human)Potency35.48131.995325.532750.1187AID624288
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.01190.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency23.51870.007215.758889.3584AID1224835; AID624030
SMAD family member 2Homo sapiens (human)Potency18.99590.173734.304761.8120AID1346859
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency18.99590.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency18.25140.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency25.11510.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency15.62490.000221.22318,912.5098AID1259247; AID743036; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency33.49150.000657.913322,387.1992AID1259377
progesterone receptorHomo sapiens (human)Potency29.84930.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency16.07940.01237.983543.2770AID1346984; AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency23.12530.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.10190.000229.305416,493.5996AID743069; AID743075
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency4.77160.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency15.58750.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency22.38720.10009.191631.6228AID1346983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency25.15670.000323.4451159.6830AID743065; AID743067
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency25.57480.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.02000.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.99531.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
corticotropin releasing factor-binding proteinHomo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
Retinoic acid receptor gamma Homo sapiens (human)Ki10.00000.00001.997510.0000AID198734
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Ki0.07500.00000.37905.6000AID157100; AID157102
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.13490.00010.579710.0000AID142687
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.13490.00011.48339.1400AID142687
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.13490.00010.68688.2600AID142687
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.00060.00020.667710.0000AID5042; AID5123
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.13490.00010.66618.2600AID142687
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.13490.00010.58908.2600AID142687
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00060.00010.601710.0000AID5042; AID5123
DRattus norvegicus (Norway rat)Ki0.01410.00010.610010.0000AID63371
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.00060.00020.590910.0000AID5042; AID5123
Gastrin/cholecystokinin type B receptorMus musculus (house mouse)Ki0.00060.00030.01660.0940AID5123
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00450.00000.437510.0000AID61079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
corticotropin releasing factor-binding proteinHomo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
Retinoic acid receptor RXR-alphaHomo sapiens (human)Kd15.01000.00040.58388.8000AID1431666
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)0.73000.00000.992210.0000AID156947
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (220)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (130)

Assay IDTitleYearJournalArticle
AID131596Fasting plasma glucose levels after 30 mg/kg peroral administration in db/db Mouse2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID15777Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID128560Brown adipose tissue weight in db/db mouse after 30 mg/kg peroral administration2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID1431675Agonist activity at RARgamma (unknown origin) expressed in human MCF-7 cells assessed as increase in AHPN induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID1431672Antagonist activity at RARgamma (unknown origin) expressed in human MCF-7 cells assessed as inhibition of AHPN induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID156293Binding affinity towards peroxisome proliferator activated receptor alpha (PPAR alpha); Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID15885Calculated partition coefficient (clogP)1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID1431674Agonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID127563Blood glucose lowering activity in hyperglycemic kk mice.2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
AID15773Tissue level at 10 mg/kg/po in wistar rats in heart1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID156290Binding affinity towards human peroxisome proliferator activated receptor alpha (PPAR alpha) by HTRF assay; Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID198734Binding affinity against Retinoic acid receptor gamma was determined in vitro by using [3H]ATRA as radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID231735Ratio between level in subcutaneous fat to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID129089Body weight of db/db mouse after 30 mg/kg peroral administration2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID132140Heart weight of db/db mouse after 30 mg/kg peroral administration2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID189061Percent reduction in triglyceride (TG) after 9 days of dosing in db/db is evaluated in rat for euglycemic and hypolipidemic activities1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID15775Tissue level at 10 mg/kg/po in wistar rats in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID1431673Agonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as increase in 9-cis-RA induced receptor transactivation at 5 to 10 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID231730Ratio between level in blood to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID510882Antidiabetic activity in ob/ob mouse assessed as reduction in fed-state whole blood glucose at 10 mg/kg, po measured on day 72010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents.
AID204506Effect on triglyceride level in male Dawley rats at 24 hr r2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID23584Pharmacokinetic Parameter (half-life) was evaluated at 10 mg/kg (p.o.) in Wistar rats1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID130224Triglyceride change in db/db mouse after 30 mg/kg peroral administration2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID15772Tissue level at 10 mg/kg/po in wistar rats in brown fat1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID199501Inhibition of Retinoic acid receptor RXR-alpha antagonist activity in vitro; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199500Inhibition of Retinoic acid receptor RXR-alpha agonist activity in vitro; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID15771Tissue level at 10 mg/kg/po in wistar rats in blood1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID14437Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID1431670Agonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as increase in 9-cis-RA induced receptor transactivation at 1 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID199486Agonistic efficacy against Retinoic acid receptor RXR-alpha was determined in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID127566Total Cholesterol change in db/db mouse after 30 mg/kg peroral administration2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID510879Antidiabetic activity in ob/ob mouse assessed as decrease in body weight at 10 mg/kg, po measured on day 152010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents.
AID231733Ratio between level in liver to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID47349Synergistic efficacy for RXR and PPAR-gamma heterodimer in vitro; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID157102Binding affinity towards peroxisome proliferator activated receptor gamma (PPAR gamma)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID231734Ratio between level in skeletal muscle to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID14574Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID510873Antidiabetic activity in ob/ob mouse assessed as whole blood glucose at 10 mg/kg, po measured on day 10 (Rvb = 199 +/- 11 mg/dL)2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents.
AID204505Effect on T4 levels in male Dawley rats at 24 hr r2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID17679Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID55968In vivo hypoglycemic activity, as reduced plasma glucose in db/db mouse type II diabetes model2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID24735Pharmacokinetic Parameter [tmax(h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID156947Peroxisome proliferator activated receptor gamma agonistic activity in HepG2 cells.2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
AID15776Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID231732Ratio between level in heart to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID199499Antagonistic efficacy for Retinoic acid receptor RXR-alpha in vitro; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID47350Synergistic transcriptional activation of RXR and PPAR-gamma heterodimer in vitro; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID1431671Activity at Nur77 LBD (unknown origin) expressed in human MCF-7 cells at 10 uM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID189026Percent reduction in blood glucose is evaluated in rat for euglycemic and hypolipidemic activities at a dose of 10 mg/kg1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID55969In vivo hypoglycemic activity compared to BRL-46953 as reduced plasma glucose in db/db mouse type II diabetes model2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID231731Ratio between level in brown fat to that of the level in plasma1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID199502Inhibition of [3H]9-cis-RA binding to Retinoic acid receptor RXR-alpha; No binding2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID1431666Binding affinity to RXRalpha-LBD (unknown origin) measured up to 120 sec by surface plasma resonance method2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID228967RXR:RAR synergy expressed as fold induction; Not applicable2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID157100Binding affinity towards human peroxisome proliferator activated receptor gamma (PPAR gamma) was determined by HTRF assay2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID15774Tissue level at 10 mg/kg/po in wistar rats in liver1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID64154In vitro binding affinity against Dopamine D2 receptor in rat striatal tissue.1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID140974In vitro binding affinity against Muscarinic acetylcholine receptors in rat brain.1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID63371Binding affinity against dopamine receptor D11994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID231522Ratio of binding affinity towards 5-HT2 to D2 receptor was measured1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID176235Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID235774Therapeutic ratio by Subcutaneous dose of administration (quotient ED50 catalepsy/ED50 climbing)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
AID231653Binding ratio of -log Ki between 5-HT2 and D2 receptors1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID142687Binding affinity against muscarinic (M) receptor1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID61521In vitro binding affinity against Dopamine receptor D1 in rat striatal tissue1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID458779Activity at HCMV US28 receptor assessed as receptor-mediated inositol phosphate response at 10 uM2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28.
AID231528Ratio of binding affinity towards D2 to muscarinic receptor (M) was measured1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID5123In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID231654Binding ratio of -log Ki between D2 and D1 receptors1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID177508In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as ED50 (mg/kg)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID231526Ratio of binding affinity towards D2 to D1 receptor was measured1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID5042Binding affinity against serotonin 5-hydroxytryptamine 2 receptor1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID114487Compound is measured for inhibition of apomorphine induced climbing affects in mice by administering the compound subcutaneously (sc) in mice1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
AID182043In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as percent inhibition1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID176500Inhibition of catalepsy in rat by subcutaneous administration of compound1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
AID61079Binding affinity against dopamine D2 receptor1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID228676Antipsychotic activity was determined from subcutaneous administration of compound in mice (ED50 catalepsy-ED50 Climbing)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID183724Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study.
AID458778Displacement of [125I]CCL5 from HCMV US28 receptor at 10 uM2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28.
AID231655Binding ratio of -log Ki between D2 and M receptors1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (20.69)18.2507
2000's12 (20.69)29.6817
2010's25 (43.10)24.3611
2020's9 (15.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.07 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials2 (3.85%)5.53%
Reviews0 (0.00%)6.00%
Reviews7 (13.46%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies18 (34.62%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
Other25 (48.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis. [NCT01765829]Phase 3104 participants (Anticipated)Interventional2012-11-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]